Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07831863 | A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy | not yet recruiting | Phase 3 | 600 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03391869 | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 339 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 |
| clinicaltrials |
| NCT06077760 | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)(INTerpath-002) | active not recruiting | Phase 3 | 868 | Merck Sharp & Dohme LLCINDUSTRY | 33 | Sep 18, 2026 | clinicaltrials |
| NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 3 | 1,160 | AstraZenecaINDUSTRY | 26 | Sep 18, 2026 | clinicaltrials |
| NCT06767514 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1(HARMONi-7) | recruiting | Phase 3 | 780 | Summit TherapeuticsINDUSTRY | 17 | Sep 18, 2026 | clinicaltrials |
| NCT07195695 | Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations | recruiting | Phase 3 | 400 | Boehringer IngelheimINDUSTRY | 28 | Sep 17, 2026 | clinicaltrials |
| NCT07365319 | A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.(TeLuRide-008) | recruiting | Phase 2 / Phase 3 | 750 | Eikon TherapeuticsINDUSTRY | 3 | Sep 17, 2026 | clinicaltrials |
| NCT07566052 | A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation | recruiting | Phase 3 | 356 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 17, 2026 | clinicaltrials |
| NCT07625644 | BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) | recruiting | Phase 3 | 550 | SystImmune Inc.INDUSTRY | 14 | Sep 17, 2026 | clinicaltrials |
| NCT07778316 | Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)(DeLLphi-315) | recruiting | Phase 3 | 400 | AmgenINDUSTRY | 5 | Sep 17, 2026 | clinicaltrials |
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | recruiting | Phase 2 / Phase 3 | 626 | Mirati Therapeutics Inc.INDUSTRY | 47 | Sep 16, 2026 | clinicaltrials |
| NCT06497556 | A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer(Krascendo 1) | active not recruiting | Phase 3 | 338 | Hoffmann-La RocheINDUSTRY | 26 | Sep 16, 2026 | clinicaltrials |
| NCT07822542 | A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | not yet recruiting | Phase 3 | 448 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT06612151 | A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302) | active not recruiting | Phase 3 | 438 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06899126 | Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer(DESTINY-Lung06) | recruiting | Phase 3 | 686 | Daiichi SankyoINDUSTRY | 23 | Sep 15, 2026 | clinicaltrials |
| NCT04804644 | Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability | active not recruiting | Phase 3 | 152 | NRG OncologyOTHER | 2 | Sep 14, 2026 | clinicaltrials |
| NCT06500455 | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | active not recruiting | Phase 3 | 274 | NRG OncologyOTHER | 4 | Sep 14, 2026 | clinicaltrials |
| NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)(DLLEVATE) | recruiting | Phase 3 | 480 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT06305754 | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | active not recruiting | Phase 3 | 550 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 11, 2026 | clinicaltrials |
| NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | active not recruiting | Phase 3 | 726 | mAbxience Research S.L.INDUSTRY | 24 | Sep 10, 2026 | clinicaltrials |
| NCT07640789 | A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) | recruiting | Phase 3 | 418 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04351555 | A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer(NeoADAURA) | active not recruiting | Phase 3 | 358 | AstraZenecaINDUSTRY | 25 | Sep 9, 2026 | clinicaltrials |
| NCT05091567 | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer(IMforte) | active not recruiting | Phase 3 | 660 | Hoffmann-La RocheINDUSTRY | 13 | Sep 9, 2026 | clinicaltrials |
| NCT07541170 | A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)(KRASCENDO 3) | recruiting | Phase 3 | 400 | Hoffmann-La RocheINDUSTRY | 6 | Sep 9, 2026 | clinicaltrials |
| NCT07809256 | A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation(LPR-2) | recruiting | Phase 3 | 15 | EuroCityClinic LLCNETWORK | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04092283 | Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 660 | National Cancer Institute (NCI)NIH | 2 | Sep 8, 2026 | clinicaltrials |
| NCT06119581 | A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer(SUNRAY-01) | recruiting | Phase 3 | 1,264 | Eli Lilly and CompanyINDUSTRY | 29 | Sep 8, 2026 | clinicaltrials |
| NCT07005128 | A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)(DeLLphi-312) | active not recruiting | Phase 3 | 350 | AmgenINDUSTRY | 26 | Sep 8, 2026 | clinicaltrials |
| NCT07361497 | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) | recruiting | Phase 3 | 850 | Bristol-Myers SquibbINDUSTRY | 32 | Sep 8, 2026 | clinicaltrials |
| NCT07361510 | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) | recruiting | Phase 3 | 750 | Bristol-Myers SquibbINDUSTRY | 36 | Sep 8, 2026 | clinicaltrials |
| NCT07291037 | Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations(TROPION-Lung17) | recruiting | Phase 3 | 400 | AstraZenecaINDUSTRY | 21 | Sep 4, 2026 | clinicaltrials |
| NCT03178552 | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)(B-FAST) | active not recruiting | Phase 2 / Phase 3 | 1,000 | Hoffmann-La RocheINDUSTRY | 27 | Sep 3, 2026 | clinicaltrials |
| NCT04035486 | A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)(FLAURA2) | active not recruiting | Phase 3 | 587 | AstraZenecaINDUSTRY | 21 | Sep 3, 2026 | clinicaltrials |
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | recruiting | Phase 3 | 851 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 3, 2026 | clinicaltrials |
| NCT07802821 | A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 556 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2026 | clinicaltrials |
| NCT06632327 | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 37 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | recruiting | Phase 3 | 621 | BioNTech SEINDUSTRY | 14 | Sep 1, 2026 | clinicaltrials |
| NCT04538664 | A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions(PAPILLON) | active not recruiting | Phase 3 | 308 | Janssen Research & Development, LLCINDUSTRY | 26 | Aug 31, 2026 | clinicaltrials |
| NCT07796100 | A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 530 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 0 | Aug 31, 2026 | clinicaltrials |
| NCT05211895 | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC(PACIFIC-8) | active not recruiting | Phase 3 | 791 | AstraZenecaINDUSTRY | 28 | Aug 28, 2026 | clinicaltrials |
| NCT01064466 | Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03811002 | Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) | active not recruiting | Phase 3 | 544 | National Cancer Institute (NCI)NIH | 2 | Aug 27, 2026 | clinicaltrials |
| NCT04025879 | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 461 | Bristol-Myers SquibbINDUSTRY | 22 | Aug 26, 2026 | clinicaltrials |
| NCT04656652 | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | active not recruiting | Phase 3 | 605 | Daiichi SankyoINDUSTRY | 26 | Aug 26, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials